{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:00:40Z","timestamp":1789545640640,"version":"build-2803163510"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1200706"],"award-info":[{"award-number":["1200706"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2017480"],"award-info":[{"award-number":["2017480"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2024876"],"award-info":[{"award-number":["2024876"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem cell transplantation and has been rapidly evolving in recent years. However, clinical trials are unable to provide patients and clinicians with long-term prognostic information nor policymakers with the full body of evidence needed to perform economic evaluation of new therapies or make reimbursement decisions. To address these limitations of the available evidence, this study aimed to develop and validate the EpiMAP Myeloma model, a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways. Risk equations were estimated using the Australian and New Zealand Myeloma &amp; Related Diseases Registry after multiple imputation of missing data. Risk equation coefficients were combined with multiple myeloma patients at diagnosis from the Registry to perform the simulation. The model was validated with 100 bootstraps of an out-of-sample prediction analysis using a 70\/30 split of the 4,121 registry patients diagnosed between 2009 and 2023, resulting in 2,884 and 1,237 patients in the training and validation cohorts, respectively. For 90% of the 120 months in the 10-year post-diagnosis period, there was no significant difference in overall survival between the validation and simulated cohorts. These results highlight that the EpiMAP Myeloma model is robust at predicting multiple myeloma disease outcomes and treatment pathways in Australia &amp; New Zealand. In the future, clinicians will be able to use the EpiMAP Myeloma model to provide personalised estimates of life expectancy to patients based on their specific characteristics, disease stage, and response to treatment. Policymakers will also be able to use the model to perform economic evaluation, to forecast the number of patients receiving treatment at different stages, and to determine the downstream impact of listing new, effective therapies.<\/jats:p>","DOI":"10.1371\/journal.pone.0308812","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T18:02:03Z","timestamp":1724781723000},"page":"e0308812","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-658X","authenticated-orcid":true,"given":"Adam","family":"Irving","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Augustson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"issue":"6","key":"pone.0308812.ref001","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/j.clml.2021.01.016","article-title":"The myeloma landscape in Australia and New Zealand: the first 8 years of the myeloma and related diseases registry (MRDR).","volume":"21","author":"K Bergin","year":"2021","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"pone.0308812.ref002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/ITT.S240886","article-title":"Immunotherapeutic and targeted approaches in multiple myeloma.","author":"O Nadeem","year":"2020","journal-title":"ImmunoTargets and Therapy."},{"issue":"6","key":"pone.0308812.ref003","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"M-V Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0308812.ref004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.","volume":"17","author":"MA Dimopoulos","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"2","key":"pone.0308812.ref005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"E Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"pone.0308812.ref006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s13187-013-0603-9","article-title":"Cancer patients\u2019 understanding of prognostic information","volume":"29","author":"LA Cartwright","year":"2014","journal-title":"J Cancer Educ"},{"issue":"15","key":"pone.0308812.ref007","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"PR Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"pone.0308812.ref008","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group.","volume":"33","author":"A Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"29","key":"pone.0308812.ref009","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project.","volume":"40","author":"M D\u2019agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0308812.ref010","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jval.2022.05.011","article-title":"An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure.","volume":"25","author":"A Nikolaou","year":"2022","journal-title":"Value Health."},{"key":"pone.0308812.ref011","doi-asserted-by":"crossref","DOI":"10.53590\/japt.02.1038","article-title":"The role of epidemiology research in economic evaluation for Health Technology Assessment.","author":"E Stamuli","year":"2022"},{"issue":"5","key":"pone.0308812.ref012","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jval.2019.01.001","article-title":"Health technology assessment challenges in oncology: 20 years of value in health.","volume":"22","author":"H Kim","year":"2019","journal-title":"Value Health"},{"key":"pone.0308812.ref013","article-title":"A review of cancer related surrogate outcomes used for PBAC decision making. Canberra, ACT: Pharmaceutical Benefits Advisory Committee","author":"Monash University Evaluation Group","year":"2023"},{"key":"pone.0308812.ref014","first-page":"274","author":"S Hussein","year":"2021","journal-title":"Myeloma and Related Conditions"},{"issue":"7","key":"pone.0308812.ref015","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.bbmt.2017.03.009","article-title":"Response assessment in myeloma: practical manual on consistent reporting in an era of dramatic therapeutic advances","volume":"23","author":"L Garderet","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"pone.0308812.ref016","doi-asserted-by":"crossref","first-page":"e0267979","DOI":"10.1371\/journal.pone.0267979","article-title":"Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.","volume":"17","author":"P Daniele","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0308812.ref017","doi-asserted-by":"crossref","first-page":"2381468320915242","DOI":"10.1177\/2381468320915242","article-title":"The diffusion of discrete event simulation approaches in health care management in the past four decades: a comprehensive review.","volume":"5","author":"S Liu","year":"2020","journal-title":"MDM policy & practice."},{"key":"pone.0308812.ref018","first-page":"1","article-title":"A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models.","author":"A Freitag","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"pone.0308812.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-016-0250-z","article-title":"Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.","volume":"16","author":"K Bergin","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"pone.0308812.ref020","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1038\/s41409-021-01308-8","article-title":"Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).","volume":"56","author":"K Bergin","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"pone.0308812.ref021","volume-title":"National Death Index","author":"Australian Insitute for Health and Welfare","year":"2023"},{"issue":"5","key":"pone.0308812.ref022","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.18324","article-title":"Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).","volume":"198","author":"Z McQuilten","year":"2022","journal-title":"Br J Haematol"},{"key":"pone.0308812.ref023","first-page":"29","volume-title":"Multiple imputation. Flexible Imputation of Missing Data","author":"DB Rubin","year":"2018","edition":"2"},{"key":"pone.0308812.ref024","volume-title":"Stata Statistical Software: Release 17","author":"StataCorp","year":"2021"},{"key":"pone.0308812.ref025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fninf.2014.00030","article-title":"The multi-modal Australian ScienceS Imaging and Visualization Environment (MASSIVE) high performance computing infrastructure: applications in neuroscience and neuroinformatics research.","volume":"8","author":"WJ Goscinski","year":"2014","journal-title":"Front Neuroinform"},{"key":"pone.0308812.ref026","unstructured":"Medicines Intelligence CRE. Protocol: Estimating overall survival in people receiving PBS-listed cancer medicines in Australian clinical practice. Final Report. Sydney, NSW: University of New South Wales; October 2022."},{"issue":"2","key":"pone.0308812.ref027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0030","article-title":"Assessment of outcomes associated with the use of newly approved oncology drugs in Medicare beneficiaries","volume":"4","author":"AK Green","year":"2021","journal-title":"JAMA Network Open"},{"key":"pone.0308812.ref028","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1057\/jos.2009.25","article-title":"Discrete event simulation for performance modelling in health care: a review of the literature","volume":"4","author":"MM G\u00fcnal","year":"2010","journal-title":"Journal of Simulation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T09:55:28Z","timestamp":1732701328000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308812"}},"subtitle":[],"editor":[{"given":"Mehmet","family":"Baysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0308812","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}